Net Loss Per Share

12 Months Ended

Dec. 31, 2024

The following table sets forth the computation of basic and diluted net loss per share for the years ended December 31, 2024 and 2023 (in thousands, except number of shares and per share amounts):


	Year Ended December 31,
Numerator:	December 31, 2024		December 31, 2023
Net loss	$	(61,183)	$	(73,447)
Net loss attributable to noncontrolling interest	109		100
Net loss attributable to Barinthus Biotherapeutics plc shareholders	$	(61,074)	$	(73,347)
Denominator:
Weighted-average ordinary shares outstanding, basic	39,348,240		38,386,491

Weighted-average ordinary shares outstanding, diluted	39,348,240		38,386,491
Net loss per share attributable to ordinary shareholders, basic	$	(1.55)	$	(1.91)
Net loss per share attributable to ordinary shareholders, diluted	$	(1.55)	$	(1.91)

Since the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share, as the inclusion of all potential ordinary share equivalents outstanding would have been anti-dilutive. For the year ended December 31, 2024, 7,285,275 (December 31, 2023: 6,207,664) potential ordinary shares issuable for stock options were excluded from the computation of diluted weighted-average shares outstanding because including them would have had an anti-dilutive effect.